Folgen

  • Ep 15 Dr. Mari Dezawa — MUSE Cell Innovations Founder and CSO

    Ep 15 Dr. Mari Dezawa — MUSE Cell Innovations Founder and CSO
    Dec 23 2025
    A profile of Dr. Mari Dezawa, whose discovery of MUSE Cells reshaped how regenerative medicine understands stress-enduring, pluripotent-like cells and their potential to support targeted joint and spine repair. To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. FULL TRANSCRIPT Dr. Mari Dezawa is one of the most influential figures in modern regenerative medicine. As Chief Scientific Officer of MUSE Cell Innovations and a professor at Tohoku University in Japan, she has reshaped the field through her groundbreaking discovery of MUSE Cells - multilineage-differentiating stress-enduring cells. Her work has provided a safer, more targeted alternative to embryonic and induced pluripotent stem cells, without the associated ethical or safety concerns. MUSE Cells are now at the center of a growing number of therapies focused on orthopedic and spine-related repair. So what exactly are MUSE Cells, and why do they matter? MUSE Cells are a rare type of adult stem cell found in bone marrow and umbilical cord tissue. They make up only one to two percent of mesenchymal stem cells, but they exhibit extraordinary properties. They survive harsh cellular stress. They can differentiate into all three germ layers - just like pluripotent cells. And most importantly, they do not form tumors. These characteristics are what make MUSE Cells so valuable. They offer the potential to regenerate tissue in a highly controlled way while reducing safety risks that have long slowed the adoption of stem cell-based treatments. One of the keys to understanding MUSE Cells is their identification. Dr. Dezawa’s team isolated them using a specific surface marker called SSEA-3. These cells can endure conditions that would destroy most other cells, and that’s where their name comes from: stress-enduring. They’ve been shown to differentiate into cell types across the ectodermal, mesodermal, and endodermal lines, supporting tissues ranging from nerve to muscle to cartilage. But unlike embryonic stem cells or iPSCs, they do so without forming teratomas or requiring genetic manipulation. So how do they work in practice? One of the most important clinical features of MUSE Cells is their ability to home to sites of injury. Whether delivered locally or systemically, they seek out damaged or inflamed tissue. Once there, they can either integrate and differentiate, or secrete beneficial factors that reduce inflammation and support surrounding cells. This is particularly relevant in orthopedic and spine care. Studies suggest MUSE Cells may support healing in the knees, hips, shoulders, and spine - areas where tissue damage is often slow to repair. Instead of simply reducing inflammation, they offer cellular-level restoration. This precision is what separates MUSE therapy from more traditional mesenchymal stem cell approaches. Where bulk MSCs may function broadly and non-specifically, MUSE Cells target the exact areas where healing is most needed, bringing structural support and regenerative signals. Dr. Dezawa’s work has moved beyond the lab and into clinical care. Through her partnership with MCI - Muse Cell Innovations - licensed providers are now offering MUSE Cell therapy in orthopedic settings. One such provider is STEMS Health in Miami Beach, one of only a few Florida clinics authorized to administer authentic Dezawa MUSE Cells. Treatments focus on joint and spine injections guided by ultrasound. No IV infusions are offered. Instead, therapy is highly localized, and delivered in a way that aligns with the scientific properties of the cells. As Chief Scientific Officer, Dr. Dezawa continues to lead the advancement of MUSE Cell research. Her team is working on GMP-compliant production lines, large-scale validation studies, and peer-reviewed research exploring how these cells can benefit not just orthopedics, but neurology, immunology, and more. Her legacy is still in progress. But what’s clear is that Dr. Mari Dezawa has introduced a new level of precision, safety, and therapeutic potential into regenerative medicine. Here are a few quick answers to common questions. What makes Dr. Dezawa’s discovery unique? She identified a subset of adult stem cells with pluripotent-like behavior that can aid tissue repair without the risks associated with iPSCs or embryonic stem cells. Are MUSE Cells safer than traditional pluripotent stem cells? Yes. MUSE Cells are non-tumorigenic and do not require genetic reprogramming, offering a more stable path to therapeutic use. Do they replace traditional MSCs? No. They complement them. MUSE Cells offer greater targeting and regenerative endurance, but MSCs remain useful in broader applications. Can they treat spine and joint issues? Current clinical use includes orthopedic pain, joint degeneration, ...
    Mehr anzeigen Weniger anzeigen
    7 Min.
  • Ep 14 Adult Stem Cells for Advanced Dry Macular Degeneration

    Ep 14 Adult Stem Cells for Advanced Dry Macular Degeneration
    Dec 22 2025
    A look at emerging clinical research showing how adult stem cell transplantation may offer early visual improvements and a new therapeutic pathway for patients with advanced dry AMD and geographic atrophy. To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. FULL TRANSCRIPT Dry age-related macular degeneration, also known as dry AMD, is one of the most common causes of irreversible vision loss in adults over 65. Its advanced form, called geographic atrophy, leads to the progressive breakdown of retinal cells and has few effective treatment options. Unlike wet AMD, which can be managed with injections, advanced dry AMD lacks therapies that can restore lost vision. This has created an urgent need for new solutions - and that’s where adult stem cells may come in. Emerging research suggests that adult stem cell transplantation could offer a new path forward. Rather than simply slowing disease progression, stem cell therapies are being studied for their ability to support visual function and preserve retinal structure. Let’s take a closer look at why adult stem cells are drawing so much interest in this area. Adult stem cells, including mesenchymal stem cells and retinal progenitor cells, are known for their anti-inflammatory and immune-modulating properties. They can be ethically sourced from bone marrow or umbilical tissue and do not carry the tumor risks associated with embryonic or pluripotent stem cells. In animal models, these cells have been shown to preserve photoreceptors, reduce inflammation in the eye, and even improve visual responses. This laid the groundwork for early human trials. Several small, early-phase clinical studies have explored subretinal injections of these cells in patients with geographic atrophy. So far, results are cautiously optimistic. Most trials have reported no serious safety issues. And in some cases, participants experienced modest improvements in visual acuity or contrast sensitivity over the course of 6 to 12 months. Imaging studies have also shown stabilization in areas of retinal atrophy, suggesting the potential for real biological impact. How do these cells work? One mechanism is paracrine signaling - where the transplanted cells don’t necessarily become new retinal cells, but instead release beneficial signals. These may enhance the survival of photoreceptors, protect the retinal pigment epithelium, and regulate inflammation. In some cases, retinal progenitor cells may even integrate into retinal layers and contribute to structural repair. The preferred method of delivery is subretinal injection, placing the cells directly into the space between the retina and its supporting layer. This ensures close contact with damaged tissue while minimizing systemic exposure and the risk of unwanted cell migration. Innovations like image-guided microinjections have improved safety and precision in these procedures, reducing the risk of complications. Of course, stem cell therapy isn’t without its challenges. Ensuring consistent quality and viability of cell batches - especially for off-the-shelf or donor-based products - is critical. Long-term durability of the benefits is still being studied. And researchers are working to identify reliable biomarkers to track whether the therapy is truly working. Most trials now include rigorous visual testing, OCT imaging, and biomarker analysis over one to two years. Regulatory agencies, including the FDA, require this kind of detailed validation before allowing stem cell therapies to move into broader use. So what comes next? Larger phase 2 trials are now underway, aiming to confirm the early signals seen in smaller studies. Some research is exploring combination approaches - pairing stem cells with gene therapies or drugs that target other parts of the disease pathway. Others are looking at personalized stem cell lines for use in high-risk individuals. And with the help of AI-assisted retinal imaging, physicians may soon be able to detect changes earlier and tailor treatment more precisely to each patient. While stem cells for dry AMD are still investigational, their potential is significant. For patients with few existing options, they represent a new frontier in vision care - one focused not just on slowing loss, but on supporting real regeneration. Here are a few frequently asked questions. Are stem cells currently FDA-approved for dry AMD? No. These therapies are still being studied and are not yet approved for routine clinical use. How are the cells delivered? Most studies use subretinal injection, placing the cells directly behind the retina near areas of damage. Can stem cells actually improve vision? Some trials have shown improvements in vision and retinal structure, but larger studies are needed to confirm these ...
    Mehr anzeigen Weniger anzeigen
    7 Min.
  • Ep 13 FDA’s Evolving Pipeline of iPSC and MSC Products

    Ep 13 FDA’s Evolving Pipeline of iPSC and MSC Products
    Dec 19 2025
    An overview of how new FDA clearances for iPSC-derived and MSC-based therapies indicate growing regulatory maturity, clearer translational pathways, and expanding commercialization potential for next-generation cell products. To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. FULL TRANSCRIPT Regenerative medicine is moving into a new era. Once dominated by experimental applications and regulatory gray zones, today’s landscape is defined by FDA-cleared products, structured trial pathways, and tighter manufacturing oversight. At the center of this shift are cell-based therapies built around two core technologies: induced pluripotent stem cells, or iPSCs, and mesenchymal stem cells, or MSCs. The FDA has already cleared dozens of therapies using or related to these cell types. This includes products like Ryoncil for pediatric graft-versus-host disease, Allocord for hematologic disorders, and MACI, used to treat cartilage injuries in the knee. These approvals signal something bigger: regulatory maturity. The FDA is actively shaping pathways to clinical use - through formal guidance, standardized testing, and accelerated programs like the Regenerative Medicine Advanced Therapy designation. Let’s break down how iPSC and MSC therapies differ and why they’re so important. iPSCs are adult cells that have been reprogrammed to act like embryonic stem cells. They can become nearly any type of cell - cardiac, neural, retinal, and more. This flexibility makes them ideal for targeted cell replacement therapies, especially in complex diseases like macular degeneration or Parkinson’s. MSCs, by contrast, are naturally multipotent. Found in bone marrow, fat, and umbilical cord tissue, these cells don’t require genetic engineering. They’re known for their ability to modulate the immune system, reduce inflammation, and support tissue repair. That makes them particularly valuable in orthopedics and inflammatory conditions. While MSCs are more common in current FDA approvals, iPSCs are gaining ground. Early-phase trials are evaluating iPSC-derived retinal cells, cardiomyocytes, and nerve-supporting cells. Many gene and cell therapies now in development incorporate iPSC technology behind the scenes. The FDA’s Center for Biologics Evaluation and Research, or CBER, has taken several steps to support these innovations. This includes guidance documents covering everything from potency testing and donor screening to good manufacturing practices. Under FDA regulations, both iPSC and MSC therapies must meet strict standards before they reach patients. That means proving cell identity, biological potency, safety, and sterility. Manufacturers are required to run viability assays, confirm genetic stability, test for contamination, and operate in certified GMP labs. For iPSCs, the risk of uncontrolled growth or tumor formation requires even more scrutiny. But regulatory clarity is only part of the story. The commercial landscape is also evolving. We’re seeing an increase in off-the-shelf allogeneic products like Ryoncil, which offer scalable access to care without requiring a custom donor for every patient. Combination therapies - pairing cells with scaffolds or delivery devices - are also becoming more common, especially in orthopedics. Another shift is happening in clinical access. Decentralized trial networks are expanding the reach of investigational therapies. Patients who don’t live near a major academic center may still be eligible to participate in early access programs. Altogether, these developments suggest that cell-based therapies are moving from niche to mainstream. For patients, this means more options and a clearer understanding of what’s available - and what’s still being studied. For providers, it means better tools, more data, and the chance to align treatment with individual patient biology. Let’s wrap up with a few key questions. What’s the difference between iPSC and MSC therapies? iPSCs are reprogrammed to become nearly any cell type and are often used in precise replacement therapies. MSCs are naturally multipotent and valued for immune modulation and tissue repair, especially in orthopedic use. Are any iPSC-based therapies FDA-approved? Most FDA-cleared therapies currently involve MSCs or related platforms. iPSC-based products are primarily in trial phases but are moving closer to approval. What is RMAT designation? The FDA’s Regenerative Medicine Advanced Therapy designation offers fast-track support for promising cell therapies showing early clinical benefit. How are these products manufactured safely? They must meet strict FDA standards for identity, potency, sterility, and safety - and must be produced in certified GMP-compliant facilities. What are today’s top uses...
    Mehr anzeigen Weniger anzeigen
    7 Min.
  • Ep 12 Umbilical Cord-Derived Muse Cells: A Cleaner, Smarter Source for Regeneration

    Ep 12 Umbilical Cord-Derived Muse Cells: A Cleaner, Smarter Source for Regeneration
    Dec 17 2025
    Unlike adipose or bone-derived cells, Dezawa MUSE Cells come from screened umbilical cord tissue - delivering consistency, purity, and clinical-grade potency for orthopedic repair. To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. FULL TRANSCRIPT Stem cell therapy is evolving, and not all stem cells are created equal. At STEMS Health, one key differentiator is the source. While many clinics use fat or bone marrow to extract stem cells, we’ve chosen a cleaner and more consistent path - umbilical cord-derived MUSE Cells. These cells offer clinical-grade purity, younger biological age, and stronger regenerative potential, particularly in orthopedic care. Let’s explore why this matters and how it impacts real-world outcomes for patients. Most people don’t realize that stem cells can be harvested from multiple tissues. Fat, bone marrow, and umbilical cord tissue are all common sources. But when it comes to precision, safety, and reproducibility, umbilical cord tissue offers distinct advantages. Dezawa MUSE Cells are extracted from screened, donated umbilical cords. These cells are part of a rare subpopulation known for their stress endurance, their ability to home to damaged tissue, and their advanced communication with surrounding cells. That makes them especially well-suited for joint and spine therapies. One of the biggest advantages of umbilical cord tissue is its biological youth. These cells are fresher, more potent, and have higher telomerase activity than cells taken from older adults. They also respond better to the bio-signaling that drives tissue healing. Collection is non-invasive and ethically performed with full donor consent. All donor tissue is rigorously screened for infections, genetic issues, and other risk factors. That ensures each batch of cells is sterile, safe, and consistent in its performance. This is not always the case with stem cells from fat or bone marrow. In those cases, the patient’s age, chronic illness, or medications can impact the number and quality of viable cells. Harvesting those cells can also involve invasive procedures and longer recovery times. By contrast, cord-derived MUSE Cells are cryopreserved and ready for use. Their consistency means we can offer higher standards of care with more predictable outcomes. Let’s talk about where and how we use these cells at STEMS Health. We focus exclusively on orthopedic applications - specifically the knee, shoulder, and spine. That includes early-stage arthritis, cartilage wear, rotator cuff injuries, and degenerative spine conditions like disc inflammation or facet joint pain. Our procedures are outpatient and image-guided, using ultrasound or fluoroscopy to ensure precise delivery. There’s no general anesthesia, and most patients resume activity within a few days. So what makes these cells work? First, they naturally migrate to the site of injury or inflammation. Once there, they help modulate the immune response, reduce inflammatory markers, and promote tissue regeneration. Their youthful biology means they stay viable longer and respond more effectively in difficult environments like low-oxygen or high-stress joints. Second, these cells are active participants in the body’s signaling systems. They help support collagen production, improve soft tissue integrity, and enhance the stability of joints over time. At STEMS Health, our focus is always on safe, ethical, and licensed care. We’re proud to be one of only a few clinics in Florida licensed by MCI - Muse Cell Innovations - to offer authentic Dezawa MUSE Cell therapy. We do not use unverified products or advertise off-label uses like IV infusion. Everything we do is supported by imaging, diagnostic review, and personalized aftercare. Let’s wrap up with a few frequently asked questions. Are cord-derived MUSE cells safe? Yes. They’re ethically sourced, lab screened, and processed under clinical-grade conditions. They meet strict standards for orthopedic use. Why not use fat or bone marrow stem cells? Those are still used in medicine, but they’re less consistent. Cord-derived MUSE cells offer cleaner sourcing, higher potency, and eliminate the need for invasive harvesting. How is the therapy delivered? Cells are injected directly into the joint or spinal region using advanced imaging guidance. The procedure is brief and requires no hospitalization. What can I expect after treatment? Many patients experience reduced pain and improved joint function over time. Results vary, but most people return to normal activity quickly. Thanks for listening. ------------------- Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described...
    Mehr anzeigen Weniger anzeigen
    6 Min.
  • Ep 11 Musecell Innovations Dezawa Cells vs. Traditional Stem Cell Therapy: The Science Behind Muse Cells

    Ep 11 Musecell Innovations Dezawa Cells vs. Traditional Stem Cell Therapy: The Science Behind Muse Cells
    Dec 17 2025

    Discover how MU cells—just 1–2% of MSCs—deliver greater regenerative potential, making them the premium choice for joint and spinal recovery.

    To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

    FULL TRANSCRIPT

    Not all stem cells are created equal. While mesenchymal stem cells, or MSCs, have been used in orthopedic therapy for years, a more refined approach is now available - one that offers greater precision and regenerative intelligence. These are MUSE Cells.

    MUSE stands for Multilineage-differentiating Stress-Enduring cells. First discovered by Dr. Mari Dezawa, MUSE cells are a rare, naturally occurring subset of MSCs that can survive in harsh environments, migrate to injured tissue, and help rebuild damaged structures through advanced signaling.

    What makes them unique is their rarity and specificity. Only one to two percent of a typical MSC sample contains MUSE cells. Isolating and using this elite group of cells allows for more focused, reliable results - especially in orthopedic applications.

    Now to be clear, traditional MSCs remain useful in many therapies. They’re widely studied and offer benefits when applied correctly. But MUSE cells take that foundation and sharpen it - giving us a targeted tool for treating complex joint and spine conditions.

    At STEMS Health in Miami Beach, we’ve seen this evolution firsthand. Our clinic focuses on using Dezawa MUSE Cells specifically for orthopedic pain and soft tissue injuries - conditions like knee arthritis, rotator cuff tears, and degenerative disc disease.

    Because MUSE cells are naturally drawn to areas of inflammation or damage, they don’t just sit in the joint space. Once injected - under precise image guidance - they begin working to regulate inflammation, promote structural support, and encourage collagen and cartilage repair.

    This makes them ideal for patients who may not be ready for surgery but need more than temporary relief from cortisone or physical therapy.

    Unlike general MSC therapies, which may vary in cell count or quality depending on how they’re harvested, MUSE cells used at STEMS Health come from screened, umbilical cord-derived sources. These cells are biologically younger and processed in cleanroom labs under strict compliance standards.

    There’s no guesswork. Each batch is traceable, purified, and prepared with orthopedic application in mind.

    Treatments are performed in-office. They do not require general anesthesia, and most patients return to their routines within a few days. Results vary, but many report improved mobility, pain reduction, and greater joint stability over time.

    Importantly, STEMS Health does not offer IV-based stem cell therapy or advertise unregulated uses. We focus exclusively on orthopedic cases and follow Florida’s formal legal framework for regenerative medicine. In fact, we’re one of just a few clinics in the state licensed to administer MUSE Cell therapy through our partnership with MCI - Muse Cell Innovations.

    If you’ve struggled with joint pain, tendon injuries, or spinal inflammation - and traditional options haven’t provided lasting relief - this next-generation approach may be worth exploring.

    Thanks for listening.

    Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

    Certain regenerative medicine procedures discussed—such as stem cell therapy, exosome therapy, or other biologic treatments—may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

    Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

    © STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.
    Mehr anzeigen Weniger anzeigen
    5 Min.
  • Ep 10 Stems Health’s Role in Florida’s Next Era of Regenerative Medicine and Muse Cell Therapy

    Ep 10 Stems Health’s Role in Florida’s Next Era of Regenerative Medicine and Muse Cell Therapy
    Nov 15 2025

    Florida is stepping into a new era of regenerative medicine—and STEMS Health is helping lead the way.

    In partnership with MCI, the global license holder for Dezawa MUSE Cells, STEMS Health is now one of only a few clinics in the state of Florida authorized to provide this advanced biologic therapy for orthopedic care.

    So what does that mean for patients?

    MUSE Cells—short for Multilineage-differentiating Stress-Enduring Cells—are a rare and potent type of adult stem cell. These cells naturally home to injured areas, survive in low-oxygen or inflamed environments, and support recovery through precise cellular communication.

    They offer an innovative path forward for people dealing with joint pain, tendon damage, or spinal issues—especially those looking to avoid or delay surgery.

    But what really sets STEMS Health apart is not just the access to MUSE Cells—it’s the way care is delivered.

    At STEMS Health, treatment begins with diagnostics: reviewing your history, imaging, and overall wellness. If MUSE Cell therapy is appropriate, the procedure is done in-office, using ultrasound guidance for precise injection into the joint or spine.

    There’s no general anesthesia, no hospital stay, and little to no downtime. Most importantly, you’re treated by a medical team that understands both regenerative science and patient-centered recovery.

    The selection by MCI wasn’t random. It’s based on STEMS Health’s commitment to clinical integrity, ethical practice, and innovation in pain management and functional medicine.

    This exclusive partnership places STEMS Health at the forefront of regenerative care—not just in Miami Beach, but throughout Florida and the southeastern U.S.

    As the demand for biologically intelligent treatments continues to rise, more people are looking for real, medically supervised alternatives to cortisone injections and surgery.

    That’s where MUSE Cell therapy comes in—and why licensed providers matter.

    Every cell used at STEMS Health is traceable, approved through MCI, and handled under strict clinical standards. That means patients receive care they can trust, with therapies that are designed for safety, efficacy, and real long-term benefit.

    As Florida continues to grow as a medical destination, STEMS Health is proud to be part of this transformation—offering personalized, regenerative care that supports healing from the inside out.

    To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

    Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

    Certain regenerative medicine procedures discussed—such as stem cell therapy, exosome therapy, or other biologic treatments—may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

    Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

    © STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.
    Mehr anzeigen Weniger anzeigen
    4 Min.
  • Ep 9 How Dezawa MUSE Cells Work Within the Body’s Repair Process

    Ep 9 How Dezawa MUSE Cells Work Within the Body’s Repair Process
    Nov 15 2025

    What Are Dezawa MUSE Cells and Why Do They Matter?

    Regenerative medicine continues to transform how physicians treat orthopedic pain and tissue injury. At the forefront of these innovations are Dezawa MUSE Cells -a unique subset of adult stem cells formally known as Multilineage-differentiating Stress-Enduring (MUSE) Cells.

    MUSE Cells are not just general stem cells. They exhibit highly specialized behavior, including:

    • Pluripotency: the ability to become different types of tissue
    • Stress endurance: survival and function in damaged or inflamed areas
    • Tissue-specific targeting: homing directly to areas of injury or degeneration

    At STEMS Health in Miami Beach, we use MUSE Cells to support orthopedic tissue healing, particularly in cases involving the spine, knees, hips, or shoulders. These cells offer a precision healing mechanism that aligns with the body’s own repair systems—without the need for surgery or long-term pharmaceuticals.

    To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

    Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

    Certain regenerative medicine procedures discussed—such as stem cell therapy, exosome therapy, or other biologic treatments—may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

    Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

    © STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.
    Mehr anzeigen Weniger anzeigen
    5 Min.
  • Ep 8 The Future of Orthopedic Recovery: How Dezawa MUSE Cells Support Joint Health and Pain Management

    Ep 8 The Future of Orthopedic Recovery: How Dezawa MUSE Cells Support Joint Health and Pain Management
    Nov 15 2025

    Orthopedic pain affects millions of Americans—whether from injury, aging, overuse, or inflammation. Conditions like knee arthritis, disc degeneration, and rotator cuff damage often lead to limited mobility and discomfort. For many patients, the options have traditionally been limited to physical therapy, cortisone shots, or surgery.

    Now, there’s a new path forward: Dezawa MUSE Cell therapy.

    At STEMS Health in Miami Beach, we are proud to be one of a select number of clinics in Florida licensed to provide this next-generation regenerative therapy. Dezawa MUSE cells are a unique subclass of stem cells that offer high performance in musculoskeletal repair—without surgery or extended downtime.

    To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
    Mehr anzeigen Weniger anzeigen
    6 Min.